Inmagene Biopharmaceuticals, one of China’s immunology drug development companies, has closed a $21 million Series B financing, led by Vertex Ventures…
Inmagene Biopharmaceuticals, one of China’s immunology drug development companies, has closed a $21 million Series B financing, led by Vertex Ventures…